Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)\u00a0shares spiked more than 20% on Monday after the Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR\u2122 robotic exoskeleton for use with Multiple Sclerosis (MS) patients.<\/p>\n\n\n\n
According to Ekso, EksoNR is the latest-generation device of the most clinically used robotic exoskeleton on the market. It was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016 and acquired brain injury (ABI) in 2020. The device was the first of its kind to receive a stroke indication, is the only exoskeleton with an ABI indication, and now is the first to receive an indication for MS.<\/p>\n\n\n\n
\u201cAs a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology. With the indications for use now expanded to include MS, the EksoNR has the potential to assist significantly more patients and improve patient mobility. We are excited to see the device benefit MS patients, providing critically needed rehabilitation solutions just as it has for patients suffering from stroke, spinal cord injury and acquired brain injury.\u201d<\/p>Steven Sherman, Chairman and Chief Executive Officer of Ekso Bionics<\/cite><\/blockquote>\n\n\n\nEksoNR is the latest-generation device of the most clinically used robotic exoskeleton on the market. It was previously cleared by the FDA for stroke and spinal cord injury rehabilitation in 2016 and acquired brain injury (ABI) in 2020. The device was the first of its kind to receive a stroke indication, is the only exoskeleton with an ABI indication, and now is the first to receive an indication for MS.<\/p>\n\n\n\n
\u201cAs a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology. With the indications for use now expanded to include MS, the EksoNR has the potential to assist significantly more patients and improve patient mobility. We are excited to see the device benefit MS patients, providing critically needed rehabilitation solutions just as it has for patients suffering from stroke, spinal cord injury and acquired brain injury.\u201d<\/p>Steven Sherman, Chairman and Chief Executive Officer of Ekso Bionics<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)\u00a0shares spiked more than 20% on Monday after the Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR\u2122 robotic exoskeleton for use with Multiple Sclerosis (MS) patients. Latest Generation Exoskeleton According to Ekso, EksoNR is the latest-generation device of… View Article<\/a>","protected":false},"author":3,"featured_media":19596,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[10,31,7,16],"tags":[],"acf":[],"yoast_head":"\nEkso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)\u00a0shares spiked more than 20% on Monday after the Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR\u2122 robotic exoskeleton for use with Multiple Sclerosis (MS) patients. Latest Generation Exoskeleton According to Ekso, EksoNR is the latest-generation device of... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T14:25:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-13T14:30:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/06\/robotic-arm-white.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1382\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton\",\"datePublished\":\"2022-06-13T14:25:19+00:00\",\"dateModified\":\"2022-06-13T14:30:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Breaking\",\"Business\",\"Technology\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\",\"url\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\",\"name\":\"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-06-13T14:25:19+00:00\",\"dateModified\":\"2022-06-13T14:30:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/","og_locale":"en_US","og_type":"article","og_title":"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth","og_description":"Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)\u00a0shares spiked more than 20% on Monday after the Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR\u2122 robotic exoskeleton for use with Multiple Sclerosis (MS) patients. Latest Generation Exoskeleton According to Ekso, EksoNR is the latest-generation device of... View Article","og_url":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-06-13T14:25:19+00:00","article_modified_time":"2022-06-13T14:30:19+00:00","og_image":[{"width":1920,"height":1382,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/06\/robotic-arm-white.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton","datePublished":"2022-06-13T14:25:19+00:00","dateModified":"2022-06-13T14:30:19+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Breaking","Business","Technology","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/","url":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/","name":"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-06-13T14:25:19+00:00","dateModified":"2022-06-13T14:30:19+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/ekso-bionics-shares-rise-after-fda-clearance-to-market-its-eksonr-robotic-exoskeleton\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"Ekso Bionics Shares Rise After FDA Clearance to Market its EksoNR\u2122 Robotic Exoskeleton"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19595"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=19595"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19595\/revisions"}],"predecessor-version":[{"id":19597,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19595\/revisions\/19597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/19596"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=19595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=19595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=19595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}